文献综述(Review)

结节性甲状腺肿术后促甲状腺激素抑制治疗研究进展

Published at: 2017年第26卷第11期

殷剑光 1 , 谈坚 1
1 上海交通大学医学院附属瑞金医院古北分院/民航上海医院 普通外科,上海 200336
通讯作者 坚 谈 Email: drqwh2003@126.com
DOI: 10.3978/j.issn.1005-6947.2017.11.015
基金:
国家自然科学基金资助项目 81172326
上海市慈善癌症研究基金资助项目

摘要

结节性甲状腺肿是普通外科领域常见疾病之一,外科手术后有较高的复发率,为后续治疗提出了挑战。而通过术后规范的甲状腺素治疗,可以使患者的术后促甲状腺激素(TSH)抑制,并控制在一个合理的水平,能明显减少结节性甲状腺肿术后的复发。笔者就结节性甲状腺肿术后TSH抑制治疗的进展进行综述。


Research progress of thyroid-stimulating hormone suppressive therapy for nodular goiter after surgery

Abstract

Nodular goiter is a common disease in the field of general surgery, and has a high postoperative recurrence rate, which poses a challenge for following treatment. Nevertheless, standardized postoperative thyroxine treatment can effectively reduce postoperative recurrence of the nodular goiter by inhibiting the thyroid-stimulating hormone (TSH) of the patients and controlling it at a proper level after operation. Here, the authors address the progress of postoperative TSH suppressive therapy for nodular goiter patients.


comments powered by Disqus

全文

引用

引用本文: 剑光 殷, 坚 谈. 结节性甲状腺肿术后促甲状腺激素抑制治疗研究进展[J]. 中国普通外科杂志, 2017, 26(11): 1466-1471.
Cite this article as: YIN Jianguang, TAN Jian . Research progress of thyroid-stimulating hormone suppressive therapy for nodular goiter after surgery[J]. Chin J Gen Surg, 2017, 26(11): 1466-1471.